Biogen Acquires Pfizer’s PF-05251749, a Potential Disease-modifying Therapy for Parkinson’s, Alzheimer’s

Biogen Acquires Pfizer’s PF-05251749, a Potential Disease-modifying Therapy for Parkinson’s, Alzheimer’s
Biogen is adding Pfizer’s PF-05251749 — a regulator of the body’s inner clock — to its group of potential disease-modifying therapies for Parkinson’s and Alzheimer’s diseases. Biogen plans to test PF-05251749 in an upcoming Phase 1 clinical trial as a treatment to correct irregular sleep wake rhythm disorder in Parkinson’s and sundowning in Alzheimer’s. Non-motor symptoms associated with Parkinson’s disease include alterations ... read more
Source: Parkinson’s News TodayPublished on 2020-01-15By Patricia Inacio, PhD